Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: A European multicenter study

SN Si-Ahmed, P Pradat, Roeland Zoutendijk, M Buti, V Mallet, C Cruiziat, K Deterding, J Dumortier, F Bailly, R Esteban, H Wedemeyer, HLA Janssen, F Zoulim

Research output: Contribution to journalArticleAcademicpeer-review

23 Citations (Scopus)


Background and aims: The combination of tenofovir disoproxil fumarate (TDF) plus emtricitabine (FTC) is used extensively to treat HIV infection and also has potent activity against hepatitis B virus (HBV) infection. The aim of this study was to assess the efficacy and tolerance of TDF + FTC in patients with chronic hepatitis B (CHB). Methods: Seventy eight consecutive CHB patients from five European centers were included. All started a TDF + FTC combination between October 2005 and March 2010. Virological, biochemical, and clinical data were recorded during follow-up. Tolerance was also monitored. Patients were classified into either treatment simplification (TS), where efficacy of the previous treatment was obtained at TDF + FTC initiation, and treatment intensification (TI), where the previous line of therapy had failed. Results: TDF + FTC was given as a TI to 54 patients (69%) and as a TS to 24(31%). Among patients with TI, 83% were males. The median baseline HBV-DNA was 4.4 log(10) IU/mL, and median alanine-transaminase (ALT) was 1.10 x ULN. Sixty percent were HBeAg positive, 47% had significant fibrosis (<= F3 Metavir equivalent), and 29% had confirmed cirrhosis. Median treatment duration was 76 weeks (interquartile range 60-116). Kaplan-Meier analysis showed that, 48 weeks after TI, the probability of being HBV-DNA becoming undetectable was 76%, and reached 94% at week 96. No viral breakthrough occurred. Patients with TS (87% males, median baseline HBV-DNA 1.1 log(10) IU/mL, median ALT 0.79 x ULN, 33% HBeAg positive, 61% with significant fibrosis) were treated for a median duration of 76 weeks. In this subgroup, all patients but one remained HBV-DNA undetectable and no ALT flare-up occurred during follow-up. Creatinine levels did not show kidney-function deterioration in either group of patients. Conclusions: After a median follow-up of >76 weeks, the TDF + FTC combination showed encouraging antiviral efficacy and a good safety profile in all patients with CHB. TDF + FTC may represent an interesting clinical option to simplify therapy and increase the barrier to resistance, which should be assessed in the long term. (C) 2011 Elsevier B.V. All rights reserved.
Original languageUndefined/Unknown
Pages (from-to)90-95
Number of pages6
JournalAntiviral Research
Issue number1
Publication statusPublished - 2011

Cite this